NextCell Pharma AB (FRA:65G) Total Liabilities: €1.22 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:65G NextCell Pharma AB FRA:65G
42 GF Score
Price €0.07
GF Value €0.06
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is NextCell Pharma AB Total Liabilities?

NextCell Pharma AB FRA:65G -5.84% 42 Total Liabilities is €1.22 Mil as of Dec. 2025. GuruFocus rates FRA:65G with a GF Score™ of 42/100 and a GF Value™ of €0.06 (Modestly Overvalued). The stock has 4 warning signs investors should review.

NextCell Pharma AB's Total Liabilities for the quarter that ended in Dec. 2025 was €1.22 Mil.

NextCell Pharma AB's quarterly Total Liabilities declined from May. 2025 (€1.02 Mil) to Aug. 2025 (€0.93 Mil) but then increased from Aug. 2025 (€0.93 Mil) to Dec. 2025 (€1.22 Mil).

NextCell Pharma AB's annual Total Liabilities increased from Aug. 2023 (€1.11 Mil) to Aug. 2024 (€1.20 Mil) but then declined from Aug. 2024 (€1.20 Mil) to Aug. 2025 (€0.93 Mil).

NextCell Pharma AB Total Liabilities Historical Data

* Premium members only.

The historical data trend for NextCell Pharma AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NextCell Pharma AB Total Liabilities Chart

NextCell Pharma AB Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.54 0.87 1.11 1.20 0.93

NextCell Pharma AB Quarterly Data
Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.84 0.90 1.02 0.93 1.22
FRA:65G
42GF Score
NextCell Pharma AB FRA:65G
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NextCell Pharma AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

NextCell Pharma AB's Total Liabilities for the fiscal year that ended in Aug. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.487+(0+0.441
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=0.93

Total Liabilities=Total Assets (A: Aug. 2025 )-Total Equity (A: Aug. 2025 )
=6.882-5.954
=0.93

NextCell Pharma AB's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.738+(0+0.486
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1.22

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=5.873-4.65
=1.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €1.22 Mil mean?
NextCell Pharma AB (FRA:65G) has a Total Liabilities of €1.22 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for NextCell Pharma AB and its competitors.
Is NextCell Pharma AB's Total Liabilities too high?
NextCell Pharma AB's current Total Liabilities is €1.22 Mil. Overall, NextCell Pharma AB has a GF Score™ of 42/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NextCell Pharma AB's Total Liabilities compare to VRTX and REGN?
NextCell Pharma AB's Total Liabilities of €1.22 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for NextCell Pharma AB and its competitors. NextCell Pharma AB's current Total Liabilities is €1.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NextCell Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, NextCell Pharma AB (FRA:65G) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.06, compared to a current price of €0.07 — trading 21% above its estimated fair value. The current Total Liabilities is €1.22 Mil. NextCell Pharma AB's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For NextCell Pharma AB (FRA:65G), the current Total Liabilities is €1.22 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NextCell Pharma AB (FRA:65G) Overvalued in 2026?

Based on GuruFocus' analysis, NextCell Pharma AB stock appears to be overvalued. The current stock price of €0.07 is trading 21% above its estimated GF Value™ of €0.06. GuruFocus considers NextCell Pharma AB to be Modestly Overvalued.

Key valuation signals for FRA:65G:

  • Total Liabilities: €1.22 Mil
  • GF Value™: €0.06 vs. price of €0.07 (21% above fair value)
  • GF Score™: 42/100 with 4 warning signs

No single metric tells the full story. See the FRA:65G stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NextCell Pharma AB Business Description

Other Exchanges NXTCL:Sweden
Address Karolinska Institutet Science Park, Halsovagen 7, Huddinge, SWE, 14157
NextCell Pharma AB is a healthcare services provider. The company is engaged in the research of stem cell and is developing the candidate drug ProTrans for the treatment of diabetes and immunosuppression in kidney transplants.
42GF Score

Get the complete analysis for FRA:65G

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.07
Price
€0.06
GF Value